Abstract 221: EARLY EXPERIENCE OF EMBOGUARD BALLOON GUIDE CATHETER IN LARGE VESSEL OCCLUSION THROMBECTOMY

Introduction Endovascular thrombectomy (EVT) is the standard of care in acute ischemic stroke secondary to large vessel occlusion in selective patients within the first 24 hours. With the evolving technology and newer generation of catheters and devices, the interest in improving the technical and procedural factors that can help better the recanalization success, clinical outcomes, and efficiency is ever‐growing. Proximal flow arrest with balloon guide catheters (BGC) has been shown to optimize revascularization success and functional outcome in stroke EVT. We aim to evaluate the performance of the Emboguard BGC (Cerenovus, Irvine, CA, USA) in anterior circulation large vessel occlusion (LVO) acute ischemic strokes. Methods A prospectively maintained EVT database was reviewed for 12 months between May 2022 to May 2023 to identify all patients at our institution with intracranial vessel occlusion who underwent EVT using Emboguard BGC. Included patients were ≥18 years with large‐vessel occlusion who presented within 24 hours of time from last‐known‐well and had baseline National Institutes of Health Stroke Scale (NIHSS) score ≥ 6. Non‐dominant M2, M3, and A2 occlusions were excluded. We collected baseline demographic, clinical, and radiographic characteristics including age, sex, co‐morbidities, baseline NIHSS score, baseline modified Rankin Score (mRS), ASPECTS score, site of occlusion, imaging at our site, and use of intravenous and/or intra‐arterial thrombolytics. Outcomes included complications, NIHSS at discharge, final modified TICI (thrombolysis in cerebral ischemia) scores including the first‐pass effect (FPE, defined as mTICI 2c/3 after first pass), modified‐FPE (defined as, mTICI 2b‐3 after first pass), symptomatic intracranial hemorrhage (SITS‐MOST definition), and death at discharge. Data were analyzed using descriptive statistics, with frequency/percent for qualitative data and median/ interquartile range (IQR) for quantitative data. Results A total of 57 patients underwent EVT using Emboguard BGC. Among them, 54.4% were female and the median age was 72 years [IQR 66‐80]. Most of the patients had MCA occlusion (68.4% with 50.9% M1 and dominant/co‐dominant M2s 17.5%) with median ASPECTS 9 [IQR 8‐10]). About one‐third of our patients received intravenous thrombolytics. Following EVT, successful recanalization defined as modified TICI (thrombolysis in cerebral ischemia) scores of 2b/3 was achieved in 56 cases (98.2%) with 1 being the median number of passes (IQR 1‐2). The first pass effect (defined as one pass with mTICI of 2c/3) was achieved in 45.6% of cases. The median National Institutes of Health Stroke Scale (NIHSS) reduced significantly from 16 (IQR 12‐22) at baseline to 4 (IQR 1.5–12) at discharge (Table). Symptomatic intracranial hemorrhage was reported in 6 cases (10.5%), death at discharge was reported in 9 cases (15.8%), and access site complications were reported in 3 cases (5.3%). Conclusion Emboguard BGC showed promising results evident by a high rate of FPE, smaller number of EVT passes and improved recanalization rates with reasonable safety profile. Comparative prospective studies are needed to confirm these results.